Psychedelics Surge: Market Madness Unleashed!
Psychedelic Shroomnado: ENVB Nukes +130%, CMND Cockrocket +57%, PASG FDA Foreskin Flop -23%!
Premarket psychedelic circlejerk exploding—Dow futures 49,653 +0.02%[1], S&P 7,149 -0.16%[1], Nasdaq 26,752 -0.27%[1]; WTI crude $85.92 +4.03% oil's getting a rimjob from supply jitters! [1] Degen drug den: ENVB funding-fueled frenzy, CMND trial tease throbbing, PASG regulatory rectum-ream—bagholders barfing while shamans squeeze the serotonin sausage! [2][3]
1) Enveric Biosciences (ENVB): “Neuroplastogen Nutbuster” vs “Dilution Dickdrain Disaster”
Why it’s loud
ENVB detonating +130% to ~$4.20 premarket porn—62M+ vol tsunami, rocketing from $1.82 close on $13.9M private placement close (incl warrants) + broader psychedelic pump from Trump PTSD fast-track EO vibes. Brain-boner breakthrough or balance-sheet bukkake?[2][4][5]
Bull case (psyche shaft supernova)
Fresh $13.9M warchest fuels EB-003 psilocybin depression trials + gov tailwinds = Phase 2 pricktease to $10, low-float squeeze sends it to orbit—degens huffing the hallucination hype! [6][7]
Bear case (reverse-split rimjob reject)
ATM dilution dump post-1:12 r/s history + cash-burn biotech blackhole = rugpull to $2 turd, short the shroom scam short-circuit! [8]
My take, first principles (plastogen prick vs placebo piss)
Strip it: Psychedelics legit for mental reset (FDA nods incoming), $13.9M credible runway but serial dilution destiny + trial turd odds = degen dice. Crude cocktease irrelevant. Rip $3.50-5, $7C/$9C shroom shaft—P$2 if warrants wank.[5]
2) Clearmind Medicine (CMND): “CMND-100 Cumshot Cure” vs “Trial Tease Tittytwister”
Why it’s loud
CMND surging +57% to ~$1.13 premarket prick—26M vol vortex, riding psychedelic wave + recent Phase I safety win on CMND-100 (DEA Schedule I alcohol addiction buster). Sobriety suppository or sobriety scam?[2][4]
Bull case (addiction assram annihilator)
FDA-approved Phase I/IIa primary endpoint smashed (safety/tolerability) + intranasal delivery deal + Trump mental health rocket = $3+ moonshot, retail rehabbing the rocket ride! [9][10]
Bear case (cash corpse cockblock)
No revenue zombie + prior dilution dumps + biotech bankruptcy bingo = crash to $0.50 delusion, fade the fermented fart! [11]
My take, first principles (DEA disruptor dong vs dehydration dud)
Core: CMND-100's ibogaine-like mechanism crushes cravings (real data), sector tailwind hot but microcap mirage + execution enema = evaporate. Oil? Snooze. Long $1-1.50, $2C/$3C trial thrust—P$0.70 Phase flop.[12]
3) Passage Bio (PASG): “Gene Therapy Gonad Grab” vs “FDA Foreskin Fumble”
Why it’s loud
PASG cratering -23% to ~$9.00 premarket pants-wetter—73K vol but post-spike slaughter, tanking on Type C FDA feedback for PBFT02 (FTD-GRN brain disease gene therapy) registrational path. Neuro nerf or negotiation nudge?[3][4]
Bull case (strategic shaft salvage)
FDA outlines likely path forward + data shared = undervalued dip-buy to $15, pipeline prick potential intact post-review! [13][14]
Bear case (regulatory rectum rupture)
"Feedback" screams delays/Phase 3 hell + cash guzzle + strategic review whiff = deathspiral to $5 dumpster, short the DNA dickdrop! [13]
My take, first principles (AAV gene jab vs approval asshole)
Basics: FTD-GRN orphan moat real (no cures), FDA chat progress but biotech binary bomb + burn-rate bitchslap = bust bait. Oil irrelevant. Dip $7.50-10, $14C/$18C pathway pump—P$6 trial toilet.[13]
Tape-Side Tactics (Shroom Squeeze or FDA Flush?)
- ENVB: $3.50-5 dilution dong; $7C/$9C funding fuckfest, P$2 warrant wipeout.[2]
- CMND: $1-1.50 trial teabag; $2C/$3C addiction assram, P$0.70 safety shart.[2]
- PASG: $7.50-10 FDA foreskin; $14C/$18C path prick, P$6 review rug.[3]
Futures flatlining, crude creaming—chase the psych pricks or short the gene gag? Ultimate degen drug dice, DYOR, NFA, pure psychedelic precum!